Skip to main content

Advertisement

Log in

Heparan sulphate epitope–expression is associated with the inflammatory response in metastatic malignant melanoma

  • Short Communication
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Heparan sulphate (HS) represents a heterogeneous class of molecules on cell membranes and extracellular matrices. These molecules are involved in a variety of biological processes, including immune responses, through their binding and functional modulation of proteins. Recently a panel of HS-epitope–specific, human single chain antibodies have been generated by phage display, facilitating analysis of the structural heterogeneity of HS in relation to pathological conditions. In a pilot study a heterogeneous staining pattern in melanoma metastases was observed with one of the clones (EW4G1). Using a double-staining technique, the expression of this epitope was studied in 12 metastatic melanoma lesions in relation to the presence of a CD3+ cell infiltrate. Different staining patterns with EW4G1 were observed in the different lesions. The different staining patterns were associated with the presence and pattern of inflammation with CD3+ cells. A pronounced staining pattern of blood vessels with EW4G1 was associated with a more or less brisk presence of CD3+ cells, while a pronounced staining of tumour cells or tumour cell matrix or absence of staining with EW4G1 was associated with absence of CD3+ cells. These results suggest a dualistic role for HS in the recruitment and intratumoural migration of CD3+ cells, depending on the location of expression of its epitope recognized by EW4G1. Further characterization of the structural diversity of HS and its function in T-cell recruitment and migration is therefore warranted, since detailed understanding of this relation may provide new targets for therapeutic intervention, such that better homing and migration of T cells (in)to tumours might be achieved in immunologically based treatment strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1A–M.

Similar content being viewed by others

References

  1. Caux F, Timar J, Lapis K, Moczar M (1990) Proteochondroitin sulphate in human melanoma cell cultures. Biochem Soc Trans 18:293

    CAS  PubMed  Google Scholar 

  2. Ey PL, Prowse SJ, Jenkin CR (1978) Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry 15:429

    Article  CAS  PubMed  Google Scholar 

  3. Hershkoviz R, Schor H, Ariel A, Hecht I, Cohen IR, Lider O, Cahalon L (2000) Disaccharides generated from heparan sulphate or heparin modulate chemokine-induced T-cell adhesion to extracellular matrix. Immunology 99:87

    Article  CAS  Google Scholar 

  4. Kato M, Wang H, Bernfield M, Gallagher JT, Turnbull JE (1994) Cell surface syndecan-1 on distinct cell types differs in fine structure and ligand binding of its heparan sulfate chains. J Biol Chem 269:18881

    CAS  PubMed  Google Scholar 

  5. Lindahl U, Kusche-Gullberg M, Kjellen L (1998) Regulated diversity of heparan sulfate. J Biol Chem 273:24979

    Article  CAS  Google Scholar 

  6. Lortat-Jacob H, Grimaud JA (1991) Interferon-gamma C-terminal function: new working hypothesis. Heparan sulfate and heparin, new targets for IFN-gamma, protect, relax the cytokine and regulate its activity. Cell Mol Biol 37:253

    CAS  PubMed  Google Scholar 

  7. Moczar M, Caux F, Bailly M, Berthier O, Dore JF (1993) Accumulation of heparan sulfate in the culture of human melanoma cells with different metastatic ability. Clin Exp Metastasis 11:462

    CAS  PubMed  Google Scholar 

  8. Nathan C, Sporn M (1991) Cytokines in context. J Cell Biol 113:981

    CAS  PubMed  Google Scholar 

  9. Salmivirta M, Lidholt K, Lindahl U (1996) Heparan sulfate: a piece of information. FASEB J 10:1270

    CAS  PubMed  Google Scholar 

  10. Selvan RS, Ihrcke NS, Platt JL (1996) Heparan sulfate in immune responses. Ann N Y Acad Sci 797:127

    CAS  PubMed  Google Scholar 

  11. Turnbull JE, Fernig DG, Ke Y, Wilkinson MC, Gallagher JT (1992) Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem 267:10337

    CAS  PubMed  Google Scholar 

  12. van de Westerlo EM, Smetsers TF, Dennissen MA, Linhardt RJ, Veerkamp JH, van Muijen GN, van Kuppevelt TH (2002) Human single chain antibodies against heparin: selection, characterization, and effect on coagulation. Blood 99:2427

    Article  PubMed  Google Scholar 

  13. van Kuppevelt TH, Dennissen MA, van Venrooij WJ, Hoet RM, Veerkamp JH (1998) Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology: further evidence for heparan sulfate heterogeneity in the kidney. J Biol Chem 273:12960

    Article  PubMed  Google Scholar 

  14. Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, Bar-Shavit R, Fuks Z (1990) Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev 9:203

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors wish to thank Marie Jadner, Karin Hellander and Catharina Tranaeus Röckert for excellent technical help in performing the immunocyto- and immunohistochemistry stainings. This research was supported by grants from the Dutch Cancer Society (grant numbers 96-1366 and 98-1801), the County Council of Östergötland and the Health Research Council in south-east Sweden.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Monique R. Bernsen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bernsen, M.R., Smetsers, T.F.C.M., van de Westerlo, E. et al. Heparan sulphate epitope–expression is associated with the inflammatory response in metastatic malignant melanoma. Cancer Immunol Immunother 52, 780–783 (2003). https://doi.org/10.1007/s00262-003-0421-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-003-0421-8

Keywords

Navigation